研究人員在日前在線出版的《自然—免疫學(xué)》期刊上報告,，免疫感應(yīng)器的活性和腫瘤逃逸免疫系統(tǒng)的能力間存在一種看似不合邏輯的聯(lián)系,。這個意料之外的結(jié)果揭示了癌癥治療的一個新靶標(biāo),。
這個輔助系統(tǒng)是由一串級聯(lián)狀的蛋白質(zhì)組成,，當(dāng)感染出現(xiàn)時,，它會像火警系統(tǒng)一樣向免疫系統(tǒng)發(fā)出警告,。一個奇怪的曲折中,，Lambris和同事發(fā)現(xiàn)腫瘤激活了一種補(bǔ)充蛋白質(zhì)C5,，這樣，在事實(shí)上抑制了免疫系統(tǒng)的抗腫瘤反應(yīng),。
這是一個令人驚異的結(jié)果,，作者通過觀察發(fā)現(xiàn)，被激活的蛋白質(zhì)征召“抑制”細(xì)胞到相應(yīng)位點(diǎn),。這些行動解除了其他免疫細(xì)胞的功能,，阻止它們殺死腫瘤。重要的是,，他們的研究顯示,，阻止C5的活性能降低小鼠腫瘤的生長，其效果相當(dāng)于抗腫瘤藥物泰素(taxol)的治療效果,。（生物谷Bioon.com）
生物谷推薦原始出處：
Nature Immunology,，9, 1225 - 1235,，Maciej M Markiewski，John D Lambris
Modulation of the antitumor immune response by complement
Maciej M Markiewski1, Robert A DeAngelis1, Fabian Benencia2,4, Salome K Ricklin-Lichtsteiner1, Anna Koutoulaki1, Craig Gerard3, George Coukos2 & John D Lambris1
The involvement of complement-activation products in promoting tumor growth has not yet been recognized. Here we show that the generation of complement C5a in a tumor microenvironment enhanced tumor growth by suppressing the antitumor CD8+ T cell–mediated response. This suppression was associated with the recruitment of myeloid-derived suppressor cells into tumors and augmentation of their T cell–directed suppressive abilities. Amplification of the suppressive capacity of myeloid-derived suppressor cells by C5a occurred through regulation of the production of reactive oxygen and nitrogen species. Pharmacological blockade of the C5a receptor considerably impaired tumor growth to a degree similar to the effect produced by the anticancer drug paclitaxel. Thus, our study demonstrates a therapeutic function for complement inhibition in the treatment of cancer.
1 Department of Pathology and Laboratory Medicine, Medical School of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
2 Center for Research on Reproduction and Women's Health, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
3 Pulmonary Division, Children's Hospital, Boston, Massachusetts 02215, USA.
4 Present address: Department of Biomedical Sciences, College of Osteopathic Medicine and Biomedical Engineering Program, Russ College of Engineering and Technology, University of Ohio, Athens, Ohio 45701, USA.
